HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma.

Abstract
Vasohibin 1, an endothelium-derived negative feedback regulator of angiogenesis, is induced by fibroblast growth factor 2 (FGF-2) and vascular endothelial growth factor A (VEGF-A). In this study, we retrospectively evaluated immunoreactivity of FGF-2 and VEGF-A as well as microvessel density (MVD) determined by expression of vasohibin 1 and CD34 (MVD-CD34) and correlated the findings with clinical outcomes of 181 patients with hepatocellular carcinoma (HCC). Double immunostaining of an endothelial marker CD34 and vasohibin 1 with Ki-67 was also performed to assess angiogenic activity of endothelial cells in HCC. The ratio of Ki-67-positive endothelial cells in vasohibin 1-positive vessels (22%) was significantly higher than that of CD34-positive vessels (9%, P < .001), suggesting the correlation between vasohibin 1 and neovascularization in endothelial cells of HCC. MVD-CD34 decreased, but the ratio of MVD determined by expression of vasohibin 1 to MVD-CD34 (vasohibin 1/CD34) increased significantly according to histologic grade. Vasohibin 1 was significantly correlated with the status of FGF-2 (P = .007) but not with that of VEGF-A (P = .055). The 10-year overall survival and the 2-year disease-free survival rates of the low vasohibin 1/CD34 group (vasohibin 1/CD34 ≤0.459) were significantly higher than those of the high vasohibin 1/CD34 group (vasohibin 1/CD34 >0.459) (survival, 48% versus 38% and 52% versus 35%; P < .001 and P < .05, respectively). In addition, vasohibin 1/CD34 in HCC patients was an independent marker of poor prognosis, as determined by multivariate analysis (risk ratio, 1.973; 95% confidence interval, 1.049-3.711; P = .035). Vasohibin 1/CD34 could identify the proliferative vessels and could be a useful biomarker for predicting the clinical outcome of HCC patients.
AuthorsKeigo Murakami, Atsuko Kasajima, Naoki Kawagishi, Satoshi Sekiguchi, Fumiyoshi Fujishima, Mika Watanabe, Yasufumi Sato, Noriaki Ohuchi, Hironobu Sasano
JournalHuman pathology (Hum Pathol) Vol. 45 Issue 3 Pg. 589-97 (Mar 2014) ISSN: 1532-8392 [Electronic] United States
PMID24444468 (Publication Type: Journal Article)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Cell Cycle Proteins
  • VASH1 protein, human
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
Topics
  • Adult
  • Aged
  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular (blood supply, metabolism, mortality, pathology)
  • Cell Cycle Proteins (metabolism)
  • Disease-Free Survival
  • Female
  • Fibroblast Growth Factor 2 (metabolism)
  • Humans
  • Liver Neoplasms (blood supply, metabolism, mortality, pathology)
  • Male
  • Middle Aged
  • Neovascularization, Pathologic (metabolism, mortality, pathology)
  • Prognosis
  • Retrospective Studies
  • Survival Analysis
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: